Industry Daily Summary: What Happened on October 14, 2026

Pfizer takes over after Enodia’s Sec61 discovery work

Enodia will lead early research to identify small-molecule inhibitors of Sec61, a cellular channel involved in making proteins.1 After discovery, Pfizer will handle clinical trials, manufacturing, regulatory submissions and commercialization.1

Enodia is due an upfront payment and may earn research, development and sales milestones, plus tiered royalties on future sales.1 The collaboration covers multiple targets that have not been disclosed.3

Zealand pays Generate $30 million upfront for obesity research

Generate will lead research on two initial programs, and Zealand can add a third through an option.2 The companies aim to develop multispecific medicines, which act on more than one biological target.2

Generate may earn up to $35 million in early preclinical milestones and nearly $1.2 billion in total milestone payments, plus royalties.2 After candidate selection, Zealand will handle clinical development, regulatory submissions and worldwide commercialization.2

Also worth knowing

• P

  Ofichem agreed to buy US drug-substance manufacturer Kinentia Biosciences, subject to approval from the Committee on Foreign Investment in the United States and other closing conditions.4

• 

  IgniteData and RealTime eClinical Solutions linked their platforms to transfer clinical records from RealTime’s eSource system through IgniteData’s Archer platform to sponsors’ data-capture systems or other selected destinations.56

Also published

• Zealand forges obesity alliance with AI specialist Generate pharmaphorum
• ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License Applied Clinical Trials
• Charles River partners with Magellan Stem Cells on cell therapy Pharmaceutical Technology
• Enodia Therapeutics Inks Pfizer Deal to Develop Sec61-Targeting Small Molecules GEN